AAV vector-based gene therapy has obtained the marketing approval for treating RPE65-associated LCA [18, 64–66], Leber hereditary optic neuropathy (LHON) [67, 68], and choroideremia (CHM) [69–71]. Here, RPE65 is linked to choroideremia.